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From the Editor’s Desk
It is time once again for the latest issue of LABRAD.
This edition is non-thematic and includes various
fresh and newfangled topics. There is an update on
the revised nomenclature of Encapsulated Follicular
Variant of Papillary Carcinoma which has shifted the
paradigm of treatment.
Hereditary thrombophilia refers to a group of
inherited disorders that is characterized by a
defect or deficiency in the natural anticoagulant
mechanisms and thus increased predisposition to
thromboembolism. There are a number of causes for
this disease and a proper screening through history
and physical examination will initially pave the way
for further testing. The article on Thrombophilia in
this issue, adequately describes the process.
Hemorrhage remains a major cause of potentially
preventable deaths. Rapid transfusion of large
volumes of blood products is required in patients
with hemorrhagic shock which may lead to a unique
set of complications. Timely recognition of these
complications and efficient management are vital
for successful outcomes. The article on massive

transfusion describes all these complications along
with monitoring and prevention.
Prealbumin is a nutritional biomarker which can
accurately assess the nutrition status for which assays
are available in the laboratory. There is an article
which elaborates the clinical association and purpose
for diagnostic evaluation.
There is also an interesting collaboration of
Pathology and Radiology with respect to a case of
Parosteal osteosarcoma and we hope that you enjoy
reading this one.
Ending on the thought provoking phrase by Socrates
“The only true wisdom is in knowing you know
nothing”, we sincerely hope that you will benefit
from these articles written by our residents and
consultants and continue to support us as always….
Bonne lecture!!
Dr Natasha Ali
Editor, LABRAD

Revised Nomenclature of Encapsulated
Follicular Variant of Papillary Carcinoma;
Now NIFTP in 2016
Dr Saira Fatima
Histopathology

The thyroid is the most frequent endocrine organ
to harbor cancer, Papillary carcinoma being the
most frequent one. Other differentiated cancer
includes Follicular carcinoma, including Hurthle cell
carcinoma as well. The C-cell derived Medullary
carcinoma accounts for approximately five percent of
thyroid cancers. The incidence of thyroid cancers has
shown three fold increase & PTC is the main type of
this rise. The follicular variant of papillary carcinoma
was first described by Dr. Rosai in 1977. Now
accounting for approximately 25 percent of the PTC.

Another term has been proposed by the Chernobyl
group of pathologists as Well differentiated tumor
of uncertain malignant potential; WDT-UMP but
because of lack of standardized & reproducible
criteria the term has not been widely adopted.
The Follicular variant of Papillary carcinoma of the
thyroid (FVPTC) has two subgroups; Encapsulated
& Invasive (Figure 1). The FVPTC has an almost
exclusive follicular pattern with nuclear features
of PTC i-e nuclear crowding, clearing, groves &
3
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Figure 1: An encapsulated follicular neoplasm. There is no capsular
invasion. (2016 SCPMG Thyroid NIFTP education module)2016 SCPMG
Thyroid NIFTP education module

pseudoinclusions. The nuclear changes may be
patchy or diffuse. They have a capsule of variable
thickness in encapsulated FVPTC (Figures 2 &

Figure 2: Exclusive follicular pattern with irregularity of follicles,
nuclear overlapping & clearing. ( 2016 SCPMG Thyroid NIFTP
education module)

Figure 3: Nuclei are elongated, crowded & irregular. Nuclear grooves
are prominent. (2016 SCPMG Thyroid NIFTP education module)

3). Capsular sampling should be done in a similar
manner as for follicular adenoma/carcinoma.
These tumors do not show high nuclear grade,
necrosis or increased mitoses (Tables 1 & 2). The
prognosis of the two subtypes varies in terms of
metastatic potential & recurrence, being virtually
absent in encapsulated FVPTC. Therefore, biologic
behavior is more in line with follicular adenomas/
carcinoma depending upon capsular or vascular
invasion. Whereas invasive FVPTC shows infiltrative
growth involving adjacent tissue, behaves more
like ordinary PTC. The molecular alterations
are detected in similar fashion. Encapsulated
FVPTC has lack of BRAF V600E mutations,
frequent RAS mutations approx. 36 persent and
rare PAX8/PPARG alterations. Invasive FVPTC
has more frequent BRAF V600E & less common
RAS mutations & RET/PTC rearrangement.
The molecular profile also supports the clinical
behavior differences & status of two distinct

Table 1: Diagnostic Criteria for Nuclear features of Papillary Carcinoma & NIFTP (2016 SCPMG Thyroid NIFTP Education Module)
Major Features

Minor Features

Features NOT seen/
Exclusion criteria

1. Encapsulation or clear demarcation

1. Dark/hypereosinophilic colloid

1. “True” papillae >1%

2. Follicular growth pattern
(<1% papillae)

2. 1rregularly-shaped follicles

2. Psammoma bodies

3. Nuclear Features of PTC (Score 2 or 3): 3. lntratumoral acellular, eosinophilic fibrosis 3. Infiltrative border (capsular or lympho
vascular invasion)
l

Enlargement/crowding/overlapping

4. “Sprinkling” sign (multifocal involvement 4. Tumor necrosis
within a single nodule)

l

Elongation

5. Follicles cleft from stroma

5. High mitotic activity (>3/1 0 HPFs)

l

Irregular contours

6. Multinucleated giant cells with in follicles

6. Cell/morphologic characteristics of other
variants of PTC

l

Grooves

l

Pseudoinclusions

l

Chromatin clearing

4
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entities.
After reviewing the long term clinical followup data,
the Endocrine pathology society at a conference
held in Boston March 2015 accepted the term Noninvasive Follicular Thyroid Neoplasm with Papillarylike Nuclei, NIFTP for Encapsulated FVPTC.
An international, multidisciplinary study of 109
patients with non-invasive EFVPTC were followed
for 10-26 years along with 101 patients of invasive
FVPTC from five different countries. The digitalized

histologic slides were reviewed by 24 pathologists
from seven countries.
The study concluded that noninvasive EFVPTC
have a very low risk of recurrence or metastasis
& should be termed as NIFTP. The recommended
management is lobectomy alone without radioactive
iodine ablation. This will remove unnecessary total
thyroidectomy surgeries & their complications.
Patients will be free of cancer stigma & psychological
burden associated with such a diagnosis.

Table 2: 2016 SCPMG Thyroid NIFTP Images for Scoring

Nuclear score: Sum of three nuclear features (each 0 or 1)
Thus, total score will vary between 0 and 3
Nuclear Features

Absent/Insufficiently expressed (0)

Present/Sufficient (1)

1) Size and Shape
• Enlargement
• Elongation
• Overlapping
2) Membrane Irregularities
• Irregular contours
• Grooves
• Intranuclear cytoplasmic
inclusions
3) Chromatin Features
• Chromatin clearing
• Margination to nuclear
membrane
• Glassv nuclei
Slight changes not sufficient
to call “present”!

Heritable Thrombophilia Screening: When &
in Whom
Dr Anila Rashid
Haematology and Transfusion Medicine

Thromboembolic abnormalities are influenced by
both heritable and environmental factor. The term
heritable thrombophilia pertains to an inherited
coagulation abnormality that has increased risk
of thrombosis. Egeberg et al first reported the risk
of venous thromboembolism with deficiency of

antithrombin, a naturally occurring anticoagulant in
1965. Since then, the deficiencies of various other
naturally occurring anticoagulants have been found
to be associated with familial thromboembolic
disorders. In late 80s testing for thrombophilia
screening became popular in unselected patients and
5
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in their relatives without any proven clinical utility.
A wide range of different tests can be employed
within heritable thrombophilia profile, although
these primarily comprise factor V Leiden, activated
protein C resistance (APCR), protein C, protein S
and antithrombin.
Several clinical guidelines emerged to guide
heritable thrombophilia investigations taking into
account, the age at presentation, site of thrombosis,
family history, and associated risk factors.
Apart from selecting the right patient for testing
many other factors contribute an affects the results
and interpretation of these investigations.
It is important for clinicians to realize the limitations
of thrombophilia testing. Thrombophilia screening
is not only expensive and time-consuming but
is often performed without a clear idea of what
to do with the results. Therefore it is important
that screening is targeted at the right people with
appropriate timing of the test as these can alter the
test interpretation. Thrombophilia screening should
ideally be performed two to three weeks after

completion of anticoagulation therapy and should
be avoided during acute thrombotic event or during
anticoagulation therapy as it may affect the test
interpretation.
According to the British Committee for Standards
in Haematology, the following are the preferred
indications for heritable thrombophilia screening:
- First thrombotic event in young age less than
		 40 years of age
- Unprovoked thrombosis
- Unprovoked recurrent thrombosis
- Thrombosis at unusual site
- Thrombosis with strong family history of
		 unprovoked recurrent thrombosis.
- Neonates and children with purpura 		
		 fulminans should be tested urgently for
		 protein C and S deficiency
- Testing is not recommended in patients with
		central venous catheter (CVC)-related thrombosis
- Testing is not indicated in patients with
		 retinal vein occlusion
- Testing for heritable thrombophilia is not
		 indicated in patients with arterial thrombosis

Massive Transfusion
Dr Imran Ahmed Siddiqui
Haematology and Transfusion Medicine

Massive transfusion is defined as the replacement
of one total blood volume in 24 hours or the
replacement of 50 percent of the blood volume in
three hours. The most common situation leading
to massive transfusion is trauma. Other situations
leading to massive transfusion, such as ruptured
abdominal aortic aneurism, liver transplant, and
obstetric catastrophes are less frequent.
Complications of Massive Transfusion
Massive blood replacement may be accompanied by
metabolic and coagulation abnormalities related to
transfusion volume and infusion rate.
Hypothermia can incite metabolic and hemostatic
derangements. Studies have shown that the
transfusion of one unit of red blood cells with
a temperature of 4°C can drop the core body
temperature 0.25°C in an average-sized patient.
During massive transfusion, the rate of citrate
6

delivery may exceed the liver’s capacity for
its clearance. Metabolic alkalosis can develop
secondarily to the accumulation of bicarbonate, the
metabolic by-product of citrate. Citrate toxicity
will result in hypocalcemia and cause symptoms
such as tingling, shivering, lightheadedness, tetany,
and hyperventilation. Rarely, hypomagnesaemia
associated myocardial depression can be observed
with severe citrate toxicity. These complications
are mostly observed in patients with liver failure.
Citrate-induced hypocalcemia is rarely associated
with clinical consequences in other massively
transfused patients.
Potassium concentrations in PRBCs can range from
seven to 77 mEq/L depending on age of stored
blood. Development of hyperkalemia will depend
on the underlying renal function, severity of tissue
injury and rate of transfusion. At transfusion rates
exceeding 100-150 ml/min, transient hyperkalemia
is frequently seen. Also, acidosis secondary to
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hypoperfusion may worsen hyperkalemia. Cardiac
effects of hyperkalemia are accentuated by
hypocalcaemia.
Coagulation abnormalities can develop
secondarily to hemodilution or diffuse intravascular
coagulopathy. Use of large volumes of asanguineous
fluids and packed red blood cells during resuscitation
in hemorrhagic shock will create platelet and
coagulation factor deficiencies.
Thrombocytopenia with platelet counts below
50,000/mm3, hypofibrinogenemia, and coagulation
factor levels below 25 percent generally occur after
the replacement of two blood volumes.
Monitoring and prevention
As volume is replaced, attention must be paid to

coagulation parameters, platelet count, and metabolic
status. The coagulation system should be frequently
monitored with measurements of the PT, aPTT,
fibrinogen concentration, and platelet count or a
viscoelastic measure preferably after each five
units of blood replaced. If the PT and aPTT exceed
1.5 times the control value, the patient should be
transfused with at least two units of fresh frozen
plasma. If the platelet count falls below 50,000/
microL, six units of random donor platelets, or one
unit of apheresis platelets, should be given.
A high capacity commercial blood warmer should
be used to warm blood components toward body
temperature when more than three units are
transfused. Risk of hyperkalemia can be reduced
by selecting red cells collected less than five or 10
days prior to transfusion. Any unit of red cells can
be washed immediately before infusion to remove
extracellular potassium.

A Review of Innovance PFA-200 System
Dr Muhammad Hasan
Haematology & Transfusion Medicine

A bench top instrument that allow rapid detection of
platelet dysfunction (hereditary and drug induced) in
citrated human whole blood.

Test Cartridges

PRINCIPLE OF PFA-200 SYSTEM
Citrated whole blood is aspirated at high shear rates
through disposable cartridges containing an aperture
within a membrane coated with either collagen and
epinephrine or collagen and ADP. These agonists
induce platelet adhesion, activation and aggregation.
Platelet plug formed at aperture diminishes and
finally stops blood flow. Time taken (seconds) from
start of test until platelets occlude the aperture is
called Closure Time (CT). CT is an indicator of
platelet function.
INNOVANCE PFA-200

Clinical applications:
l
l
l
l
l

l

Helps to detect inherited, acquired and druginduced platelet dysfunction.
Detects Von Willebrand disease.
Assesses the anti-platelet effect of aspirin.
Evaluates platelet dysfunction in children.
Evaluates platelet dysfunction in multiple
clinical settings such as high bleeding risk
surgery, high risk pregnancy and menorrhagia.
Detects effects of Clopidogril tablets in patients
undergoing therapy with a P2Y12receptor antagonist.
7
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Test cartridges: It has three test cartridges of different composition used for different purposes.
Test Cartridge

Composition

Use

Dade PFA
Collagen/EPI
Test Cartridge

2 ug equine Type I collagen Primary cartridge used to detect platelet dysfunction induced by intrinsic plate10 ug epinephrine bitartrate let defects, VWD or exposure to platelet inhibiting agents. Can provide effective
assessment of pre-surgical therapy with DDVAP

Dade PFA Collagen/
ADP
Test Cartridge

2 ug equine Type I collagen Is used to indicate if an abnormal result obtained with Col/EPI Test Cartridge
may have been caused by effect of ASA or medications containing ASA.
50 ug adenosine-5’Col/EPI Test Cartridge is sensitive to Aspirin
diphosphate (ADP)

Innovance P2Y
Test Cartridge

20 ug ADP
5 ng Prostaglandin E1
(PGE1)
125 ug ionic Calcium
No Collagen

Is used to detect platelet dysfunction induced by blockade of platelet P2Y12receptors in patients undergoing therapy with a P2Y12-receptor antagonist

CARTRIDGE SENSITIVITY SPECIFICITY
Col/EPI
Col/ADP
P2Y12

100%
97%
98.5%

97%
92%
93.7%

Advantages of the PFA 200:
l

l
l

l

l
l

l

8

Only small volumes of citrated venous blood [800μL) are needed and so the test is useful
for investigating platelet function in children.
Can be used by non-skilled personnel and is both rapid and automated
The PFA 200 was designed as a screen to detect problems with primary hemostasis and
in part to replace the bleeding time and in this respect it is better standardized.
Measurement of platelet function at high shear [physiological] rates whereas Light
Transmittance Aggregometry (LTA) measures platelet function at low shear rates i.e. less
physiological.
Relatively insensitive to clotting factor deficiencies
High negative predictive value – i.e. if the PFA200 gives a normal result then with some
exceptions primary haemostasis is intact [Exceptions: Storage Pool Disorder, Primary
Secretion Defects, mild Type 1 VWD].
Due to the dedicated cartridge for P2Y12 receptor, Clopidogril resistance can be
analyzed.
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Radiologic-Pathologic Correlation
Osteogenic Tumors
Dr Nasir Ud Din and Dr Dawar Khan
Histopathology and Radiology

A 28 year female patient presented with long history
of painless swelling of left upper arm. An x-ray was
performed which showed a huge heavily calcified
mass attached to cortex of the humerus with a broad
base wrapping around it. On the medial side of
humerus, an incomplete lucency between the tumor
and underlying bone is seen (Figure 1)
An incision biopsy was
performed and sent for
histologic evaluation.
Histological
examination showed a
bone forming tumour
covered by cartilage
cap which exhibited
moderate cellularity
and atypia (Figure
2A,B). Beneath
cartilage cap are
parallel seams of
woven bone with
intervening mildly
atypical spindle cells
(Figure 2C,D).
Figure 1

Based on radiological and histological features, a
diagnosis of Parosteal osteosarcoma was rendered.

Figure 2A,B

Parosteal
osteosarcoma is a low
grade malignant bone
forming neoplasm
that accounts about
four percent of all
osteosarcomas.
A slight female
predominance is seen
and most patients are
young. Approximately
two third of cases
arise on the surface
of distal posterior
femur. The department
of Pathology and

Laboratory Medicine
archives has 23 cases of
parosteal osteosarcoma
diagnosed over a period
of 13 years. These
showed a mean age of
26 years and 68 percent
of cases involved distal
femur.
Radiological differential
diagnosis of parosteal
osteosarcoma are
osteochondroma
and conventional
osteosarcoma. A
radiolucent line
Figure 2C,D
separating base of tumor
from adjacent cortex is seen in approximately 58
percent cases of parosteal osteosarcoma. Most cases
of osteochondroma attach to underlying cortex by a
pedicle, not a broad base. Conventional osteosarcoma
extensively involves the cortex with secondary
involving periosteum.
Histologically parosteal osteosarcoma differentiated
from osteochondroma by presence of parallel seams
of woven bone containing intervening mild atypical
spindle cells. Osteochondroma has trabeculae of mature
lamellar bone with intertrabecular spaces containing
either fatty or hematopoietic marrow. The cartilage
cap in osteochondroma has columnar arrangement
of chondrocytes. Approximately 50 percent cases of
parosteal osteosarcoma cartilage differentiation either
in the form of cartilage nodules or a cartilage cap. The
cartilage cap however lacks columnar arrangement.
Around 15-25 percent cases of parosteal
osteosarcomas show dedifferentiation in the form
of high grade sarcoma. Recent advances show
CDK4 and MDM4 gene amplification in >85
percent cases of parosteal osteosarcoma. Prognosis
is excellent with 91 percent overall survival at five
years. Around six percent cases metastasize by five
years and 11 percent at 10 years which are mostly
dedifferentiated.
9
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Pre Albumin or Transthyretin - A Useful
Biomarker in the Assessment of Malnutrition
Dr Sibtain Ahmed
Chemical Pathology

A useful biomarker of nutritional status should
readily respond to variations in nutrient intake,
remain unaffected by other diseases, easy analytical
procedures available, comparatively low-cost, and
possess a shorter half-life. Traditionally, albumin
levels have been in common utilization by clinicians
and laboratories globally as predictor of nutritional
status, but they themselves suffer from certain
limitations including lack of significant response
to recent fluctuations in nutrition; retain a longer
half-life (20 days) and moreover also get influenced
by hydration status and renal parenchymal diseases.
Albumin characteristically takes 14 days to return to
baseline when the pool has been depleted.
Published literature has suggested prealbumin or
transthyretin as one such nutritional biomarker which
can accurately assess the nutrition status. It is mainly
produced by the liver and assays of quantification
are readily available for lab utilization, have a short
half -life (two days), less affected by liver disease,
and have one of the highest ratios of essential to
nonessential amino acids, making it a distinct marker
for assessing malnutrition.
Clinical associations with high or low serum
prealbumin concentrations:
Serum concentrations of prealbumin are influenced
by a large number of factors
A) Causes of increased concentrations of 		
prealbumin
1. Increased synthesis: exogenous
		 corticosteroids or anabolic steroids;
		 NSAIDS; insulin-like growth factor-1 (IGF		 1), either endogenous or exogenous.
2. Decreased catabolism: chronic renal failure;
		 renal tubular damage.
3. Distributional or hydration changes: standing
		 position prior to blood sampling; acute
		dehydration.
B) Causes of decreased concentrations
1. Age: infancy, childhood, and advanced age.
10

2. Decreased synthesis: acute phase response
		 (infection, inflammation, trauma, 		
		 malignancy, etc.); administration of IL-6;
		 estrogens (endogenous or exogenous); acute
		 total starvation; moderate to severe liver
		 disease (may be due in part to inflammation
		 and/or estrogen); thyroid disease, especially
		endemic goiter.
3. Distributional changes: increased vascular
		 permeability; ascites or pleural fluid;
		 recumbent position prior to blood sampling
		 (e.g., in bedridden patients); acute 		
		hemodilution.
4. Increased loss/catabolism: acute blood loss;
		protein-losing enteropathy; nephrotic syndromes.
Intended use of Prealbumin
Prealbumin is primarily used for evaluating
nutritional status, chiefly in monitoring the response
to nutritional support in the acutely ill patient.
Furthermore, Prealbumin response has found to have
a significant correlation with patient outcome making
it a useful prognostic marker. In a 1995 consensus
statement a panel recommended checking serum
Prealbumin levels in all patients admitted to the
hospital with malnutrition or nutritional risk factors
such as advanced age, diabetes, hypertension, and
renal disease. The panel also recommended that
patients with levels <15 mg per dL (150 mg per L)
receive a consultation from the hospital’s nutritional
team. Prealbumin has also been proven to be a good
indicator of probabilities of developing re-feeding
syndrome upon commencement of refeeding, via
either the enteral, parenteral or oral routes.
Thus to conclude Prealbumin should therefore be
employed as a pivotal component of an overall
assessment strategy as it is a sensitive biomarker
of insufficient nutrient intake. Furthermore its
levels should be interpreted with caution in acute
alcoholism, steroid use, and zinc deprivation.
Additionally serial monitoring of Prealbumin
assessed twice weekly during hospital stay can well
sensitize the physician about the patient’s nutritional
status.
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Urinary Tract Infections (UTIs) in Children:
A Pictorial Guide
Dr Fizza Farooqui										
Microbiology

Unexplained fever >38°C
Test urine WITHIN 24 hours!!

Table 1: Diagnostic criteria for UTI in children

National Institute of Health and Clinical Excellence
(NICE)1:
Age Group

Urgent microscopy (>5 cells per high
power field)

Dipstick
analysis (D/R)

Culture (Clean catch/
suprapubic/ in/out catheters)

√

-

√ (+ other sites e.g. blood,
cerebrospinal fluid)

√

Debatable

√

√

√

√

<3 months

3 months - <3
years

>3 years

American Academy of Pediatrics (AAP)2: Pyuria and growth of ≥50,000 colony forming units of a single
urinary pathogen.

Urine culture: 24 hour growth on CLED medium. >105 colony forming units of lactose fermenting gram
negative rods
11
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Collection
NICE

AAP
In/out catheter or suprapubic
aspiration

Clean catch urine
Urine collection bags and pads
(contamination!)

In/out catheter or suprapubic aspiration

Empiric Antibiotic Therapy

NICE
AAP
NONE!! (↑ antibiotic resistance, inconvenience, lack Antibiotic based on desired route of administration, local
of compliance, ↑cost )
antibiogram, then susceptibility results for 7-14 days

Other Management
NICE

AAP

Regular bladder emptying

Ultrasound of kidneys and bladder for structural anomalies

General hygiene measures

Voiding cystourethrogram for complex cases

Adequate fluid intake
Breast feeding
Circumcision

Thus, a high index of suspicion, appropriate sample collection and testing followed by regular follow up to
prevent recurrent UTI remain the mainstay for management of urinary tract infections in children.

Validation of Test Methods in a Clinical
Laboratory: A Brief Overview of the
Concepts, Aims and Procedures
Ms Farhat Jahan
Chemical Pathology

Method validation is the process of “establishing
documented evidence” which provides high degree
of assurance that product (equipment/analyte)
meets the requirements for the intended analytical
12

applications. The definition used for “validation”
in the ISO standard 8402 is “confirmation by
examination and provision of objective evidence that
the particular requirements for a specific intended
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use are fulfilled”. Without method validation
experiments, there can be no assurance that the
results reported are reliable and fit for the purpose
defined. All laboratory tests/equipment must be
validated before being introduced in patient testing
to ensure that the values results reported meets the
clinical expectations with an anticipated degree of
reliability. Once the process is all equipment/analytes
needs to be revalidated following any change in
reagents, instrumentation or protocol and to ensure
quality assurance (QA) after a certain period of
time. Method validation is required to evaluate and
document inaccuracy and imprecision in a method
performance. The clinical requirements should be
pre-determined prior to initiating method validation
studies (figure 1). Tests using complex methodology
usually require more thorough validation studies than
moderately complex or simple methods.

methods
It is a series of processes through which we test
our system to verify or validate the performance
specifications claimed by the manufacturer. A full
validation is needed for new methods or when
major changes to an existing method affect the
scope. Partial validation is performed on previously
validated methods that have undergone minor
modifications. Generally, fewer tests are needed
and are based on the potential effects of the
modifications. Cross-validation can be used as means
of assessing inter-laboratory execution of the same
method.
A basic process of initiating and implementing
method validation in a clinical laboratory is shown in
figure 1. The main focus of whole method validation
process is identifying the sources of potential
analytical errors, including both random
error and systemic error. Where random
error is the amount of inherent variation
in the method and systemic error is the
difference from the true value.
The various performance characteristics
which are evaluated during method
validation process include:
l

Accuracy: Closeness of the 		
agreement between a test result and
the true or target value. It is
expressed as the difference between
the averages results obtained from
two different methods (Bias). It 		
is a measure of systemic error.

Precision: Precision, repeatability or
reproducibility is the degree of
agreement among repeated
measurements (closeness of
measurements to each other or 		
results consistency) of the same
Figure 1: Flow Chart Showing Basic Process of Method Validation of a New Lab Test at a
substance on the same sample, or
Clinical Laboratory
on separate samples collected as
close as possible in time and place. Precision is a
These are certain conditions when method validation
measure of random error.
may be required:
l

l
l
l
l
l

New method is developed/introduced in clinical
laboratory
Modification of established methods
Every six months to ensure optimal performance
of methods
When established methods are transferred to
different test facilities
For comparison of two or more laboratory test

l

l

Linearity: It is the ability of method to produce
the test results that are proportional to the
analyte concentration and the relationship
between the observed and target value can be
graphically represented by a straight line.
Analytical Measurement Range: Range of 		
numeric results a method can produce without
13
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any special specimen pre-treatment, such as dilution
that is not part of the usual analytic process.
l

l

l

Limit of Detection: It is the lowest amount of
analyte which can be detected, but not
necessarily quantitated as an exact value.

l

l

Limit of Quantitation: The lowest 			
concentrations of an analyte in a sample that can
be quantitatively determined accurately with
suitable precision.
Analytical Specificity: The ability of a method
to detect only the analyte that it was designed
to detect without interference from some other
substances.

Analytical Sensitivity: The lowest concentration
of the analyte which the test can reliably detect
as positive in the given matrix”.
Reference Intervals: in this method validation
study healthy population is tested for certain
analytes in order to characterize the expected
range of test values for that population. The
laboratory should establish or verify existing
reference intervals for each method and species
before reporting results.

All activities conducted during validating a test
need to be documented. Documenting the whole
method validation processes along with evidence is
important before implementing a method in service.

Clinical Significance of Stone Composition
Analysis in Urolithiasis Management
Dr Hafsa Majid and Dr Abdullah Saleem Ghelli
Chemical Pathology

Urolithiasis refers to the formation of stones anywhere
in the urinary system. These stones may form as result of
one or more of several factors that include an unhealthy
diet, infections, inherited metabolic disorders and
lithiasis due to secondary reasons from other illnesses.
Renal stones are usually classified according to
their composition. Different conditions can cause
differences in the composition of the stones.
Therefore stone analysis is important to better
understand the cause of the stones and treat them
appropriately. Renal stones are analyzed to evaluate
the constituents of a stone, to help determine the
cause of its formation and also to guide treatment and
prevent its reoccurrence.
Analysis of Kidney Stone Composition
According to American Urological Association
Guidelines, all patients with history of urolithiasis
should have at least one stone analyzed before
initiating treatment. Second analysis is only indicated
if physician suspects change in stone composition. The
recommended techniques for renal stones analysis are:
l
l

14

X-ray crystallography
Infrared spectroscopy

At section of Chemical Pathology, Department of
Pathology and Laboratory Medicine, Aga Khan
University, renal stones are now analyzed by Fourier
transform infrared spectroscopy (FTIR), a semi
quantitative methodology. It helps identify not only
composition of renal stones but can help differentiate
between compositions of stone surface and core
(nidus). Composition of stone core or the nidus is
important in managing patient, as it may be entirely
different from that of the peripheral layers and
may lead to changes in management of patient. For
accurate analysis proper collection and transport of
stone is necessary.
Special Instructions for Collection and Transport
of Kidney Stones
l
l
l
l

Specimen source is required and should be 		
mentioned on the request slip.
The entire stone should be sent for analysis.
Stone must be sent clean and dry (ambient 		
temperature preferred for transport).
The stone should not be directly placed in a bag.
If specimen is received in a bag, either transfer
the stone into a screw-capped plastic container
or place the bag containing stone in screwcapped plastic container.
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l

Following stones would be rejected: embedded
in tissue, sent with collection devices, sent in
fluid-filled containers, or sent with significant
non-stone debris.

Management of Renal Stones
Medical treatment of renal stones involves supportive
care and administration of agents, such as analgesics,
NSAIDS, antidiuretics, antibiotics, alkalinizing agents
etc. While for stones that are ≥7 mm and are unlikely
to pass spontaneously may require some type of
surgical procedure, such as percutaneous nephrostomy,
extracorporeal shockwave lithotripsy (ESWL),
ureteroscopy, percutaneous nephrostolithotomy etc.
The composition of a stone can be an important factor
in its disintegration by lithotripsy and subsequent
elimination of fragments. Stones made of uric acid
and calcium oxalate dihydrate have a better coefficient
of fragmentation than those made of calcium oxalate

monohydrate and cystine. Hard stones respond
poorly to ESWL; e.g. stones made of cystine, calcium
oxalate monohydrate, and brushite. Nowadays
open surgery is usually reserved for cases with
anatomical abnormalities or in cases where ESWL
is contraindicated. In cases of inherited metabolic
disorders, use of enzyme replacement or gene therapy
may be required; types of stones, their causes and
management are summarized in table below.
To conclude the renal stone composition is not only
important for guidance of treatment, but it can also play
an essential role in determining the underlying cause
of urolithiasis. There are many underlying causes of
renal stones and knowing the composition of a stone
influences clinical decisions. Thus, instructing the patient
to retrieve a passed stone or instructing the urologist,
who is performing a stone-related procedure, to save and
send a stone fragment for analysis is an important part of
the approach to prevent recurrent stone formation.

Table: Types of Renal Stone, their Causes and Management.
S#

1.

2.

Stone Type

Calcium
oxalate

Ammonium
hydrogen
phosphate

3.

Calcium
phosphate

4.

Uric acid

5.

6.

Genetic Stones

Drugs related
stones

Causes

Management

• Hyperoxaluria
• Inherited metabolic disorder of
oxalate
• Low water intake or dehydration

• ESWL for Wedellite
• Surgical removal for hard Whewellite
stone
• Enzymes replacement in inherited 		
metabolic disorders
• Increased fluid intake
• Hydrochlorthiazide (for increased Ca)
• Citrate supplementation
• Pyridoxine

Subtypes
Calcium oxalate
Monohydrate
(Whewellite)
Calcium oxalate
Dihydrate
(Weddellite)

•
•
•
•

Struvite

• UTI (urea splitting bacteria)

Surgery + antibiotics

• Hyperparathyroidism, Distal
Renal tubular acidosis (low urine
pH)
• UTI (Alkaline urine pH)
• Other metabolic disorders

• ESWL for Dahllite
• Brushite extremely hard stones
resisting ESWL, may require
chemolytic treatment or open surgery

•
•
•
•

•
•
•
•

Brushite, Dahllite

Uricite, ammonium
urate

Hypercalciuria
Hypocitraturia
Low water intake or dehydration
High salt consumption

UTI (urea splitting bacteria)
Alkaline Urine pH
Bowel disease
Hyperuricosuria

Urine alkalinization
Antibiotics
Purine restriction
Allopurinol

• Cystine crystallization
preventive drugs
• High fluid intake, >3 L per day
• Surgical removal for large Cystine 		
stones

Cystine

Inherited cystinuria

Xanthine

Inherited xanthinria

• Purine restriction
• High fluid intake

2,8-dihydroxyadenine

Inherited metabolic disorder

• High fluid intake
• Uricosuric drugs

Long term treatment with specific
drug

• Stop the causative agent
• High fluid intake
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